CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


risankizumabWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug2953 placebo for risankizumab Wiki 1.00
drug871 Estradiol patch Wiki 1.00

Correlated MeSH Terms (3)


Name (Synonyms) Correlation
D014456 Ulcer NIH 0.41
D003092 Colitis NIH 0.41
D003093 Colitis, Ulcerative NIH 0.41

Correlated HPO Terms (2)


Name (Synonyms) Correlation
HP:0002583 Colitis HPO 0.41
HP:0100279 Ulcerative colitis HPO 0.41

There is one clinical trial.

Clinical Trials


1 A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects With Ulcerative Colitis Who Responded to Induction Treatment in M16-067 or M16-065

The purpose of this study is to evaluate safety and efficacy of risankizumab in participants with ulcerative colitis (UC) in participants who responded to induction treatment with risankizumab in a prior AbbVie study of risankizumab in UC. This study consists of three sub-studies: Substudy 1 is a 52-week, randomized, double-blind, placebo-controlled maintenance study; Substudy 2 is 52-week, randomized, exploratory maintenance study; and Substudy 3 is an open-label long-term extension study for participants who completed Substudy 1 or 2, or participants who responded to induction treatment in Study M16-067 with no final endoscopy due to the Covid-19 pandemic.

NCT03398135 Ulcerative Colitis (UC) Drug: risankizumab Drug: placebo for risankizumab
MeSH:Colitis Colitis, Ulcerative Ulcer
HPO:Colitis Ulcerative colitis

Primary Outcomes

Description: Clinical remission per Adapted Mayo Score.

Measure: Sub-Study 1: Percentage of Participants with Clinical Remission per Adapted Mayo Score

Time: Week 52

Secondary Outcomes

Description: Endoscopic remission per endoscopy subscore.

Measure: Sub-Study 1: Percentage of Participants with Endoscopic Remission

Time: Week 52

Description: Clinical remission per full Mayo Score.

Measure: Sub-Study 1: Percentage of Participants with Clinical Remission per Full Mayo Score in Participants with a Full Mayo Score of 6 to 12 at Baseline (of Induction)

Time: Week 52

Description: Clinical remission per Adapted Mayo Score.

Measure: Sub-Study 1: Percentage of Participants who Discontinued Corticosteroid Use, Remained Corticosteroid Free for 90 days, and Achieved Clinical Remission per Adapted Mayo Score in Participants Taking Steroids at Baseline (of induction).

Time: Week 52

Description: Clinical remission per Adapted Mayo Score.

Measure: Sub-Study 1: Percentage of Participants with Clinical Remission per Adapted Mayo Score in Participants with a Clinical Remission at Week 0

Time: Week 52

Description: Participants who discontinued corticosteroid use.

Measure: Sub-Study 1: Percentage of Participants who Discontinued Corticosteroid Use in Participants who were Taking Steroids at Baseline (of induction)

Time: Week 52

Description: Endoscopic improvement per endoscopy subscore.

Measure: Sub-Study 1: Percentage of Participants with Endoscopic Improvement in Participants with Endoscopic Improvement at Week 0

Time: Week 52

Description: Clinical response per Adapted Mayo score.

Measure: Sub-Study 1: Percentage of Participants with Clinical Response per Adapted Mayo Score

Time: Week 52

Description: Endoscopic improvement per endoscopy subscore.

Measure: Sub-Study 1: Percentage of Participants with Endoscopic Improvement

Time: Week 52

Description: Participants with an event that results in admission to the hospital.

Measure: Sub-Study 1: Percentage of Participants with Hospitalization

Time: Through Week 52

Description: The UC-SQ is a patient questionnaire to assess severity of ulcerative colitis symptoms.

Measure: Sub-Study 1: Change in Ulcerative Colitis Symptom Questionnaire (UC-SQ)

Time: Week 0 to Week 52

Description: Histologic remission per Geboes Score.

Measure: Sub-Study 1: Percentage of Participants with Histologic Remission

Time: Week 52

Description: Mucosal healing defined as endoscopic and histologic remission.

Measure: Sub-Study 1: Percentage of Participants with Mucosal Healing

Time: Week 52

Description: The IBDQ is used to assess the quality of life of patients with inflammatory bowel disease.

Measure: Sub-Study 1: Change in Inflammatory Bowel Disease Questionnaire (IBDQ)

Time: Week 0 to Week 52

Description: Participants who underwent surgery related to UC.

Measure: Sub-Study 1: Percentage of Participants with Ulcerative Colitis (UC)-Related Surgeries

Time: Through Week 52

Description: The SF-36 is an indicator of overall health status.

Measure: Sub-Study 1: Change in 36-Item Short Form Health Status Survey (SF-36)

Time: Week 0 to Week 52

Description: The FACIT-Fatigue is a validated tool that measures an individual's level of fatigue during their usual daily activities over the past week.

Measure: Sub-Study 1: Change in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue)

Time: Week 0 to Week 52

Description: The SFS, RBS, and endoscopic subscore describe disease severity.

Measure: Sub-Study 1: Percentage of Participants with Stool Frequency Subscore (SFS), Rectal Bleeding Subscore (RBS), and Endoscopic Subscore of 0

Time: At Week 52

Description: The Stool Frequency Subscore ranges from 0 (normal) to 3 (severe disease). A negative change in Stool Frequency Subscore indicates improvement.

Measure: Sub-Study 1: Percentage of Participants with Stool Frequency Subscore (SFS) ≤ 1

Time: Through Week 52

Description: The Rectal Bleeding Subscore ranges from 0 (normal) to 3 (severe disease). A negative change in Rectal Bleeding Subscore indicates improvement.

Measure: Sub-Study 1: Percentage of Participants with Rectal Bleeding Subscore (RBS) = 0

Time: Through Week 52

Description: The Partial Adapted Mayo Score is a composite of the following sub-scores: SFS and RBS.

Measure: Sub-study 1: Change from Baseline of Induction in Partial Adapted Mayo Score

Time: Through Week 52

Description: The Full Mayo Score ranges determines disease severity. A negative change in Full Mayo Score indicates improvement.

Measure: Sub-Study 1: Change in Full Mayo Score

Time: Week 0 to Week 52

Description: The Stool Frequency Subscore ranges from 0 (normal) to 3 (severe disease). A negative change in Stool Frequency Subscore indicates improvement.

Measure: Sub-Study 1: Change in SFS

Time: Week 0 to Week 52

Description: The Rectal Bleeding Subscore ranges from 0 (normal) to 3 (severe disease). A negative change in Rectal Bleeding Subscore indicates improvement.

Measure: Sub-Study 1: Change in RBS

Time: Week 0 to Week 52

Description: High sensitivity C-reactive protein was analyzed by a central laboratory. The median percent change from week 0 in CRP is assessed at each time point.

Measure: Sub-Study 1: Change in High Sensitivity C-reactive Protein (hs-CRP)

Time: Week 0 to Week 52

Description: Stool samples were analyzed by a central laboratory for fecal calprotectin (FCP)qualitative measurement. Results are reported for participants in each category.

Measure: Sub-Study 1: Change in Fecal Calprotectin (FCP)

Time: Week 0 to Week 52

Description: The Ulcerative Colitis Endoscopic Index of Severity (UCEIS) is defined as an assessment of the endoscopy findings scoring system for additional exploratory analyses.

Measure: Sub-Study 1: Change from Baseline in Ulcerative Colitis Endoscopic Index of Severity (UCEIS)

Time: At Week 52

Description: The European Quality of Life 5 Dimensions (EQ-5D-5L) is a standardized instrument used to measure health-related quality of life that can be used in a wide range of health conditions and treatments.

Measure: Sub-Study 1: Change in European Quality of Life 5 Dimensions (EQ-5D-5L)

Time: Week 0 to Week 52

Description: The WPAI UC questionnaire was used to assess work and activity impairment due to symptoms of ulcerative colitis. The self-administered questionnaire measures the effect of the participant's health problems on work and daily activities in the previous week, specifically, the number of hours missed from work due to health problems, how much the subject's health problems affected work productivity, and how much the subject's health problems affected regular activities. Low scores indicate little or no impact of health problems on work and activities, and a negative change in the WPAI score indicates improvement.

Measure: Sub-Study 1: Change in Work Productivity and Impairment Questionnaire - UC (WPAI UC)

Time: Week 0 to Week 52

Description: The Partial Adapted Mayo Score is a composite of the following sub-scores: SFS and RBS.

Measure: Sub-study 1: Time to Loss of Clinical Response per Partial Adapted Mayo in Patients with Response per Partial Adapted Mayo

Time: At Week 0

Description: The PGIS is a response scale that describes the severity of the participants disease.

Measure: Sub-Study 1: Change in Patient Global Impression of Severity (PGIS)

Time: Week 0 to Week 52

Description: The PGIC is a response scale. The participant will be asked by the Investigator or qualified designee to rate their change in their disease status.

Measure: Sub-Study 1: Change in Patient Global Impression of Change (PGIC) scores

Time: Through Week 52

Description: Participants who discontinued corticosteroid use, in participants taking steroids at baseline (of induction).

Measure: Sub-Study 1: Percentage of Participants who Discontinued Corticosteroid Use, in Participants Taking Steroids at Baseline (of Induction).

Time: Through Week 52

Description: Clinical remission per Adapted Mayo score, in participants taking steroids at baseline (of induction).

Measure: Sub-Study 1: Percentage of Participants who Discontinued Corticosteroid Use and Achieved Clinical Remission, in Participants Taking Steroids at Baseline (of Induction).

Time: Through Week 52

Description: Clinical remission per Adapted Mayo score, in participants taking steroids at baseline (of induction).

Measure: Sub-Study 1: Percentage of Participants who Discontinued Corticosteroid Use for 90 Days and Achieved Clinical Remission, in Participants Taking Steroids at Baseline (of Induction).

Time: Through Week 52

Description: Clinical remission per Adapted Mayo score, in participants taking steroids at baseline (of induction).

Measure: Sub-Study 1: Percentage of Participants who Discontinued Corticosteroid Use for 90 Days and SFS ≤ 1 (and not Worse than Baseline of Induction) and RBS = 1 and Achieved Clinical Remission, in Participants Taking Steroids at Baseline (of Induction).

Time: Through Week 52

Description: The Partial Adapted Mayo Score is a composite of the following sub-scores: SFS and RBS.

Measure: Sub-Study 3: Percentage of Participants with Clinical Response per Partial Adapted Mayo Score

Time: Through Week 300

Description: Clinical remission per Adapted Mayo Score.

Measure: Sub-Study 3: Percentage of Participants with Clinical Remission per Adapted Mayo Score with Endoscopy

Time: Through Week 300

Description: Clinical response per Adapted Mayo score.

Measure: Sub-Study 3: Percentage of Participants with Clinical Response per Adapted Mayo Score with Endoscopy

Time: Through Week 300

Description: The Partial Adapted Mayo Score is a composite of the following sub-scores: SFS and RBS.

Measure: Sub-Study 3: Time to Loss of Clinical Response per Partial Mayo Score

Time: Through Week 300

Description: Clinical remission per Adapted Mayo Score.

Measure: Sub-Study 3: Time to Loss of Clinical Remission per Adapted Mayo Score with Endoscopy

Time: Through Week 300

Description: Clinical response per Adapted Mayo score.

Measure: Sub-Study 3: Time too Loss of Clinical Response per Adapted Mayo Score with Endoscopy

Time: Through Week 300

Description: The Partial Adapted Mayo Score is a composite of the following sub-scores: SFS and RBS, in participants taking steroids at baseline (of induction).

Measure: Sub-Study 3: Percentage of Participants Who Discontinued Corticosteroid Use with Clinical Response per Partial Adapted Mayo Score in Participants Taking Steroids at Baseline (of Induction).

Time: Through Week 300

Description: Endoscopic improvement per endoscopy subscore.

Measure: Sub-Study 3: Percentage of Participants with Endoscopic Improvement

Time: Through Week 300

Description: Endoscopic remission per endoscopy subscore.

Measure: Sub-Study 3: Percentage of Participants with Endoscopic Remission

Time: Through Week 300

Description: Mucosal healing defined as endoscopic and histologic remission.

Measure: Sub-Study 3: Percentage of Participants with Mucosal Healing

Time: Through Week 300

Description: Histologic remission per Geboes Score.

Measure: Sub-Study 3: Percentage of Participants with Histologic Remission

Time: Through Week 300

Description: The UC-SQ is a patient questionnaire to assess severity of ulcerative colitis symptoms.

Measure: Sub-Study 3: Change in Ulcerative Colitis Symptom Questionnaire (UC-SQ)

Time: Week 0 to Week 300

Description: Participants with an event that results in admission to the hospital.

Measure: Sub-Study 3: Percentage of Participants with Hospitalization

Time: Through Week 300

Description: Participants who underwent surgery related to UC.

Measure: Sub-Study 3: Percentage of Participants with Ulcerative Colitis (UC)-Related Surgeries

Time: Through Week 300

Description: The FACIT-Fatigue is a validated tool that measures an individual's level of fatigue during their usual daily activities over the past week.

Measure: Sub-Study 3: Change in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue)

Time: Week 0 to Week 300

Description: The SF-36 is an indicator of overall health status.

Measure: Sub-Study 3: Change in 36-Item Short Form Health Status Survey (SF-36)

Time: Week 0 to Week 300

Description: The IBDQ is used to assess the quality of life of patients with inflammatory bowel disease.

Measure: Sub-Study 3: Change in Inflammatory Bowel Disease Questionnaire (IBDQ)

Time: Through Week 300

Description: The WPAI UC questionnaire was used to assess work and activity impairment due to symptoms of ulcerative colitis. The self-administered questionnaire measures the effect of the participant's health problems on work and daily activities in the previous week, specifically, the number of hours missed from work due to health problems, how much the subject's health problems affected work productivity, and how much the subject's health problems affected regular activities. Low scores indicate little or no impact of health problems on work and activities, and a negative change in the WPAI score indicates improvement.

Measure: Sub-Study 3: Change in Work Productivity and Impairment Questionnaire - UC (WPAI UC)

Time: Through Week 300

Description: The European Quality of Life 5 Dimensions (EQ-5D-5L) is a standardized instrument used to measure health-related quality of life that can be used in a wide range of health conditions and treatments.

Measure: Sub-Study 3: Change in European Quality of Life 5 Dimensions (EQ-5D-5L)

Time: Through Week 300

Description: The Rectal Bleeding Subscore ranges from 0 (normal) to 3 (severe disease). A negative change in Rectal Bleeding Subscore indicates improvement.

Measure: Sub-Study 3: Change in RBS

Time: Through Week 300

Description: The Stool Frequency Subscore ranges from 0 (normal) to 3 (severe disease). A negative change in Stool Frequency Subscore indicates improvement.

Measure: Sub-Study 3: Change in SFS

Time: Through Week 300

Description: Stool samples were analyzed by a central laboratory for fecal calprotectin (FCP)qualitative measurement. Results are reported for participants in each category.

Measure: Sub-Study 3: Change in Fecal Calprotectin (FCP)

Time: Through Week 300

Description: High sensitivity C-reactive protein was analyzed by a central laboratory. The median percent change from week 0 in CRP is assessed at each time point.

Measure: Sub-Study 3: Change in High Sensitivity C-reactive Protein (hs-CRP)

Time: Through Week 300

Description: The PGIS is a response scale that describes the severity of the participants disease.

Measure: Sub-Study 3: Change in Patient Global Impression of Severity (PGIS)

Time: Week 0 to Week 300

Description: The PGIC is a response scale. The participant will be asked by the Investigator or qualified designee to rate their change in their disease status.

Measure: Sub-Study 3: Change in Patient Global Impression of Change (PGIC) scores

Time: Through Week 300

Description: Participants who discontinued corticosteroid use, in participants taking steroids at baseline (of induction).

Measure: Sub-Study 3: Percentage of Participants Who Discontinued Corticosteroid Use, in Participants Taking Steroids at Baseline (of Induction).

Time: Through Week 300


Related HPO nodes (Using clinical trials)